BR112020011746A2 - compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5 - Google Patents

compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5 Download PDF

Info

Publication number
BR112020011746A2
BR112020011746A2 BR112020011746-3A BR112020011746A BR112020011746A2 BR 112020011746 A2 BR112020011746 A2 BR 112020011746A2 BR 112020011746 A BR112020011746 A BR 112020011746A BR 112020011746 A2 BR112020011746 A2 BR 112020011746A2
Authority
BR
Brazil
Prior art keywords
amino
pyrimidine
pyrrolo
compound
diol
Prior art date
Application number
BR112020011746-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Prathap Sreedharan Nair
Sanjeev Anant KULKARNI
Milind Dattatraya Sindkhedkar
Venkata P. Palle
Rajender Kumar Kamboj
Ganesh Bhausaheb GUDADE
Sachin Sethi
Dipak Raychand Lagad
Chetan Sanjay Pawar
Mahadeo Bhaskar Tryambake
Chaitanya Prabhakar KULKARNI
Anil Kashiram Hajare
Balasaheb Arjun Gore
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of BR112020011746A2 publication Critical patent/BR112020011746A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112020011746-3A 2017-12-13 2018-12-13 compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5 BR112020011746A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201721044886 2017-12-13
IN201721044886 2017-12-13
IN201821024634 2018-07-02
IN201821024634 2018-07-02
IN201821040029 2018-10-23
IN201821040029 2018-10-23
PCT/IB2018/060015 WO2019116302A1 (en) 2017-12-13 2018-12-13 Substituted bicyclic heterocyclic compounds as prmt5 inhibitors

Publications (1)

Publication Number Publication Date
BR112020011746A2 true BR112020011746A2 (pt) 2020-11-17

Family

ID=65036860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020011746-3A BR112020011746A2 (pt) 2017-12-13 2018-12-13 compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5

Country Status (28)

Country Link
US (2) US11459330B2 (ja)
EP (1) EP3724190B1 (ja)
JP (1) JP7282778B2 (ja)
KR (1) KR20200098598A (ja)
CN (1) CN111712498B (ja)
AU (1) AU2018385664B2 (ja)
BR (1) BR112020011746A2 (ja)
CA (1) CA3085259A1 (ja)
CL (1) CL2020001576A1 (ja)
CR (1) CR20200263A (ja)
CU (1) CU24621B1 (ja)
DK (1) DK3724190T3 (ja)
ES (1) ES2927860T3 (ja)
GE (1) GEP20227359B (ja)
HR (1) HRP20221207T1 (ja)
HU (1) HUE059945T2 (ja)
IL (1) IL274936B2 (ja)
LT (1) LT3724190T (ja)
MX (1) MX2020006181A (ja)
PE (1) PE20211444A1 (ja)
PH (1) PH12020550881A1 (ja)
PL (1) PL3724190T3 (ja)
PT (1) PT3724190T (ja)
RS (1) RS63623B1 (ja)
SG (1) SG11202004934QA (ja)
UA (1) UA126349C2 (ja)
WO (1) WO2019116302A1 (ja)
ZA (1) ZA202003528B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2020256166A1 (en) * 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN114126614A (zh) * 2019-05-30 2022-03-01 安杰斯制药公司 作为prmt5抑制剂的杂环化合物
JP2022536337A (ja) * 2019-06-10 2022-08-15 ルピン・リミテッド Prmt5阻害剤
KR20220086628A (ko) 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물
US20220372040A1 (en) * 2019-10-25 2022-11-24 Accent Therapeutics, Inc. Mettl3 modulators
WO2021111322A1 (en) 2019-12-03 2021-06-10 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
CA3179189A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP2023536589A (ja) 2020-07-31 2023-08-28 タンゴ セラピューティクス, インコーポレイテッド Mtap欠損及び/またはmta蓄積癌の治療に有用なピペリジン-1-イル-n-ピリジン-3-イル-2-オキソアセトアミド誘導体
CA3203205A1 (en) 2021-01-19 2022-07-28 Mandar Ramesh Bhonde Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251431A1 (en) 2002-07-22 2004-02-09 Cambridge University Technical Services Ltd. Synthesis of discodermolide
WO2005016878A2 (en) 2003-08-13 2005-02-24 Isis Pharmaceuticals, Inc. METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
EP2049490A1 (en) 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
WO2010036213A1 (en) 2008-09-26 2010-04-01 Agency For Science, Technology And Research 3-deazaneplanocin derivatives
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
CA2803842C (en) 2010-06-30 2020-01-07 Fujifilm Corporation Nicotinamide derivative or salt thereof as syk-inhibitors
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
ES2608053T3 (es) 2011-08-19 2017-04-05 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibidores de ácido graso sintasa
WO2013157022A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
BR112014030630A2 (pt) 2012-06-08 2017-06-27 Gilead Sciences Inc inibidores macrocíclicos de vírus flaviviridae
WO2014008223A2 (en) 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EA027908B1 (ru) 2012-12-21 2017-09-29 Эпизим, Инк. Ингибиторы prmt5 и их применения
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2935241A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
CA2942833A1 (en) 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
SG11201602662YA (en) 2013-10-10 2016-05-30 Araxes Pharma Llc Inhibitors of kras g12c
RU2697512C2 (ru) 2014-05-22 2019-08-15 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она и 1,3-дигидро-пирроло[3,2-c]пиридин-2-она
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102493854B1 (ko) 2014-06-25 2023-01-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 (s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
CR20170384A (es) 2015-02-24 2017-11-16 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5

Also Published As

Publication number Publication date
US20220267339A1 (en) 2022-08-25
US20210163486A1 (en) 2021-06-03
HUE059945T2 (hu) 2023-01-28
PH12020550881A1 (en) 2021-04-05
HRP20221207T1 (hr) 2022-12-09
KR20200098598A (ko) 2020-08-20
ES2927860T3 (es) 2022-11-11
CL2020001576A1 (es) 2020-11-06
WO2019116302A1 (en) 2019-06-20
CN111712498A (zh) 2020-09-25
CR20200263A (es) 2020-07-26
CN111712498B (zh) 2023-09-29
IL274936B1 (en) 2023-05-01
RS63623B1 (sr) 2022-10-31
CU24621B1 (es) 2022-09-08
EP3724190A1 (en) 2020-10-21
EP3724190B1 (en) 2022-07-06
US11459330B2 (en) 2022-10-04
GEP20227359B (en) 2022-03-10
PL3724190T3 (pl) 2022-10-31
MX2020006181A (es) 2020-09-03
JP2021506793A (ja) 2021-02-22
UA126349C2 (uk) 2022-09-21
PE20211444A1 (es) 2021-08-05
ZA202003528B (en) 2022-05-25
IL274936A (en) 2020-07-30
CU20200051A7 (es) 2021-03-11
CA3085259A1 (en) 2019-06-20
AU2018385664A1 (en) 2020-07-02
PT3724190T (pt) 2022-10-03
US11952380B2 (en) 2024-04-09
DK3724190T3 (da) 2022-10-10
JP7282778B2 (ja) 2023-05-29
LT3724190T (lt) 2022-10-10
AU2018385664B2 (en) 2022-06-02
SG11202004934QA (en) 2020-07-29
IL274936B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
BR112020011746A2 (pt) compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5
TWI714567B (zh) 作為lsd1抑制劑之雜環化合物
JP2022506887A (ja) 窒素含有縮合複素環系shp2阻害剤化合物、製造方法及び使用
CA2897333C (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
KR101716011B1 (ko) Btk 활성의 억제제인 알킬화된 피페라진 화합물
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
KR20180043794A (ko) 피라졸 피리미딘 유도체 및 이의 용도
JP6888006B2 (ja) Mnk1およびmnk2を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
TW201307292A (zh) 經取代之6,6-稠合含氮雜環化合物及其用途
KR20140096100A (ko) 이환 피페라진 화합물
CN113135910A (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
KR20110015699A (ko) 디아자카르바졸 및 사용 방법
JP7357146B2 (ja) アザヘテロアリール化合物及びその使用
CA3114259A1 (en) Aminonorbornane derivative and manufacture method therefor and use thereof
CA3181909A1 (en) 4-ethynylpyridine derivatives useful as gcn2 inhibitors
KR20200138306A (ko) 헤테로시클릭 화합물
CN114380818A (zh) 吡唑并吡啶类化合物,及其药物组合物、制备方法和用途
CN112694477B (zh) 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途
CN116249692A (zh) 吡唑类化合物及其制备方法和用途
EA041973B1 (ru) Замещенные бициклические гетероциклические соединения в качестве ингибиторов prmt5
WO2020247679A1 (en) Wdr5 inhibitors and modulators
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
JP2024518784A (ja) 含窒素複素環式化合物
OA19533A (en) Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors.
KR20110015627A (ko) 치환된 피롤 및 사용 방법

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]